SAPU Bioscience emphasizes the publication examined by experts, which TGFB2 has linked to survival in younger patients with pancreatic cancer

The data supports a further evaluation of the investigations -antiSense -101 (Trabedersen) as a TGFB2 -Targeted approach in the pancreatic duct valley capacity.

San Diego, California, July 17, 2025 (Globe Newswire) – SAPU Biosciences, LLC (SAPU), a frequent subsidiary of GMP Biotechnology Limited (GMP -Bio), in cooperation with oncotelic therapeutic agents, Inc. Diseases today have the publication of new translational research results to evaluate the TGFB2 expression and promotional ethylation as a potential prognostic marker for pancreatic -Duktaladenocarcinoma (PDAC) highlighted. The article, “The TGFB2 expression and methylation predict overall survival in patients with pancreatic -duktal -Denocarcinoma,” appears in the International Journal of Molecular Sciences (IJMS). The work included investigators who are connected Sapu.

Access to publication: DOI 10.3390/IJMS26136357 (Open Access over IJMS).

Study highlights

Clinical data from the OT–101 P001 PDAC study suggest that TGFB2 receives an additional evaluation in younger patients; In a treated subgroup marked by low IL–6, Median OS was 12.7 months.†

Investigative commentary

“These results give the clinicers a practical way to layer patients and to design more precise, age -focused studies, which is urgently required to improve the results of this notoriously fatal illness. Professor Wasif Saif, MDCo-author of the study and director of the Eisenberg Center for Translational Therapeutika and co-director of the gastric genology oncology program at the Karmanos Cancer Institute. He added further. “The analysis shows that high TGFB2 expression in patients below 65 (TGFB2 high median compared to low median OS: 17.9 vs. 66.9 months), but not in older cohorts, was significantly associated with a reduced overall survival (OS). In addition, it showed in older cohorts. Data from one Pancreas-duktal adenoma study using OT-101, an anti-oligonucleotide, which TGFB2 aimed at, supported these findings that young patients treated with OT-101, compared to untreated control persons, who have a different biomarker monitoring with a recent, younger subset. challenge to clinics more often.